Tuesday, October 8, 2024
HomeNEWSSOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid...

SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing, Business News

The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months BOSTON and ROLLE, Switzerland, Sept. 10, 2024 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid
Read More

RELATED ARTICLES
- Advertisment -

Most Popular